CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
WO1989006692A1
(en)
*
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
CA2045231A1
(en)
*
|
1990-07-19 |
1992-01-20 |
Victor Ling |
Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
TW254946B
(no)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
PL181304B1
(pl)
|
1994-07-22 |
2001-07-31 |
Lilly Co Eli |
Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP3437685B2
(ja)
*
|
1995-09-12 |
2003-08-18 |
株式会社東芝 |
交直変換装置の制御保護システム
|
DE69622183D1
(de)
|
1995-11-07 |
2002-08-08 |
Kirin Brewery |
Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6426383B1
(en)
*
|
1997-05-28 |
2002-07-30 |
Nalco Chemical Company |
Preparation of water soluble polymer dispersions from vinylamide monomers
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
SE9704545D0
(sv)
*
|
1997-12-05 |
1997-12-05 |
Astra Pharma Prod |
Novel compounds
|
EA004436B1
(ru)
|
1998-09-29 |
2004-04-29 |
Уайт Холдингз Корпорейшн |
Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
|
US6288082B1
(en)
*
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
*
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6432979B1
(en)
*
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6277983B1
(en)
*
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
WO2001051919A2
(en)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
GB0008368D0
(en)
*
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
US7306801B2
(en)
*
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
ES2228932T3
(es)
*
|
2000-08-11 |
2005-04-16 |
Wyeth |
Procedimiento de tratamiento del carcinoma positivo de estrogenos.
|
TWI286074B
(en)
*
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
IL157898A0
(en)
|
2001-04-06 |
2004-03-28 |
Wyeth Corp |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
ZA200603888B
(en)
*
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
NZ529877A
(en)
|
2001-06-01 |
2006-08-31 |
Wyeth Corp |
Antineoplastic combinations
|
AU2002345670A1
(en)
|
2001-06-14 |
2003-01-02 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
UA77200C2
(en)
*
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
NZ533118A
(en)
|
2001-11-27 |
2006-07-28 |
Wyeth Corp |
3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
|
ES2485841T3
(es)
*
|
2002-02-01 |
2014-08-14 |
Ariad Pharmaceuticals, Inc |
Compuestos que contienen fósforo y usos de los mismos
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US7026330B2
(en)
*
|
2002-05-30 |
2006-04-11 |
The Children's Hospital Of Philadelphia |
Methods for treatment of acute lymphocytic leukemia
|
JP2005529162A
(ja)
*
|
2002-06-05 |
2005-09-29 |
セダーズ−シナイ メディカル センター |
キナーゼインヒビターを使用して癌を処置する方法
|
WO2004004644A2
(en)
|
2002-07-05 |
2004-01-15 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
AU2003256847A1
(en)
*
|
2002-07-26 |
2004-02-16 |
Advanced Research And Technology Institute At Indiana University |
Method of treating cancer
|
US20040096436A1
(en)
*
|
2002-08-02 |
2004-05-20 |
Regents Of The University Of California |
Methods for inhibiting protein kinases in cancer cells
|
US20040209930A1
(en)
*
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
CA2514479A1
(en)
*
|
2003-01-23 |
2004-08-05 |
T.K. Signal Ltd. |
Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
|
CN1437942A
(zh)
|
2003-02-08 |
2003-08-27 |
杭州华卫制药技术开发有限公司 |
注射用长春瑞滨粉针剂及制备方法
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
UA80756C2
(en)
*
|
2003-04-22 |
2007-10-25 |
Wyeth Corp |
Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
BR122016015715B8
(pt)
|
2003-07-23 |
2021-05-25 |
Bayer Healthcare Llc |
composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
BRPI0413255A
(pt)
|
2003-08-01 |
2006-10-03 |
Wyeth Corp |
uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
|
JP2007502819A
(ja)
|
2003-08-19 |
2007-02-15 |
ワイス・ホールディングズ・コーポレイション |
4−アミノ−3−キノリンカルボニトリルの調製方法
|
US7399865B2
(en)
*
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
AU2003304497B2
(en)
|
2003-09-15 |
2010-06-24 |
Wyeth Llc |
Substituted quinolines as protein tyrosine kinase enzyme inhibitors
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
WO2005049021A1
(en)
|
2003-11-03 |
2005-06-02 |
Oy Helsinki Transplantation R & D Ltd |
Materials and methods for inhibiting neointimal hyperplasia
|
US7981618B2
(en)
|
2003-11-05 |
2011-07-19 |
Board Of Regents Of The University Of Texas System |
Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
|
AR046639A1
(es)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
WO2005055943A2
(en)
*
|
2003-12-04 |
2005-06-23 |
Amr Technology, Inc. |
Vinorelbine derivatives
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
WO2005094357A2
(en)
*
|
2004-03-31 |
2005-10-13 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
DE602004025386D1
(de)
|
2004-05-28 |
2010-03-18 |
Hetero Drugs Ltd |
Neue stereoselektive synthese von benzimidazolsulfoxiden
|
EP1766068A4
(en)
*
|
2004-06-04 |
2010-03-03 |
Genentech Inc |
EGFR Mutations
|
EP1781815A2
(en)
|
2004-07-23 |
2007-05-09 |
AstraZeneca AB |
Method of predicting the responsiveness of a tumour to erbb receptor drugs
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
WO2006044453A1
(en)
|
2004-10-13 |
2006-04-27 |
Wyeth |
Analogs of 17-hydroxywortmannin as pi3k inhibitors
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
US20060084666A1
(en)
*
|
2004-10-18 |
2006-04-20 |
Harari Paul M |
Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
|
US20080268034A1
(en)
|
2005-01-07 |
2008-10-30 |
Girish Karanth |
Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN113975393A
(zh)
|
2005-02-03 |
2022-01-28 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
JP2008535477A
(ja)
|
2005-02-24 |
2008-09-04 |
アムジエン・インコーポレーテツド |
上皮成長因子受容体変異
|
SI1859793T1
(sl)
|
2005-02-28 |
2011-08-31 |
Eisai R&D Man Co Ltd |
Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
|
JP5159303B2
(ja)
|
2005-03-03 |
2013-03-06 |
武田薬品工業株式会社 |
放出制御組成物
|
JP5336174B2
(ja)
|
2005-03-09 |
2013-11-06 |
アボット・ラボラトリーズ |
トラスツズマブによる治療の候補患者を確認するための診断方法
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20060235006A1
(en)
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
EP1871371A2
(en)
|
2005-04-14 |
2008-01-02 |
Wyeth |
Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
|
US20110045459A1
(en)
|
2005-04-21 |
2011-02-24 |
Mischel Paul S |
Molecular determinants of EGFR kinase inhibitor response in glioblastoma
|
MX2007013465A
(es)
|
2005-04-28 |
2008-01-21 |
Wyeth Corp |
Tanaproget micronizado, composiciones y metodos para preparar las mismas.
|
WO2006120557A1
(en)
|
2005-05-12 |
2006-11-16 |
Pfizer Inc. |
Anticancer combination therapy using sunitinib malate
|
CN101203494A
(zh)
|
2005-05-25 |
2008-06-18 |
惠氏公司 |
合成经取代3-氰基喹啉和其中间物的方法
|
MX2007014773A
(es)
*
|
2005-05-25 |
2008-02-20 |
Wyeth Corp |
Metodo para preparar 3-ciano-quinolinas e intermedios hechos de esta forma.
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
MX2008000666A
(es)
|
2005-07-15 |
2008-03-13 |
Wyeth Corp |
Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato.
|
US20100105031A1
(en)
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
BRPI0520530A2
(pt)
|
2005-10-05 |
2009-09-29 |
Astrazeneca Uk Ltd |
método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb
|
WO2007050495A2
(en)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
US20070104721A1
(en)
|
2005-11-04 |
2007-05-10 |
Wyeth |
Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
|
TW200803842A
(en)
*
|
2005-11-04 |
2008-01-16 |
Wyeth Corp |
Antineoplastic combinations of temsirolimus and sunitinib malate
|
US20090306101A1
(en)
|
2005-11-11 |
2009-12-10 |
Flavio Solca |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
PT1951274E
(pt)
|
2005-11-24 |
2009-12-14 |
Aicuris Gmbh & Co Kg |
Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
|
JP2007145745A
(ja)
|
2005-11-25 |
2007-06-14 |
Osaka Univ |
変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
|
CA2632213A1
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
CA2644841C
(en)
|
2006-04-07 |
2013-07-16 |
Novartis Ag |
Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
US20100113299A1
(en)
|
2008-10-14 |
2010-05-06 |
Von Hoff Daniel D |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
CN101449162B
(zh)
|
2006-05-18 |
2013-07-31 |
分子压型学会股份有限公司 |
确定针对病状的个性化医疗介入的***和方法
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
EP2032989B2
(en)
|
2006-06-30 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Igfbp2 biomarker
|
SI2068880T1
(sl)
|
2006-09-18 |
2012-08-31 |
Boehringer Ingelheim Int |
Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
EP2073823A1
(en)
|
2006-10-13 |
2009-07-01 |
Medigene AG |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
US20100143340A1
(en)
|
2006-12-13 |
2010-06-10 |
Schering Corporation |
Methods and compositions for treating cancer
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
CN101605540A
(zh)
|
2006-12-14 |
2009-12-16 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
WO2008076143A1
(en)
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
CN101678022A
(zh)
|
2006-12-21 |
2010-03-24 |
弗特克斯药品有限公司 |
可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
|
JP2010515758A
(ja)
|
2007-01-12 |
2010-05-13 |
ワイス エルエルシー |
錠剤中錠剤組成物
|
EP2126127B1
(en)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
JP5284967B2
(ja)
|
2007-02-01 |
2013-09-11 |
武田薬品工業株式会社 |
打錠障害を生じない錠剤製剤
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
EP1978106A1
(en)
|
2007-04-07 |
2008-10-08 |
Universitätsklinikum Hamburg-Eppendorf |
Detection of ESR1 amplification in endometrium cancer and ovary cancer
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
WO2008130910A1
(en)
|
2007-04-19 |
2008-10-30 |
Wellstat Biologics Corporation |
Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
SI2200431T1
(sl)
|
2007-09-10 |
2016-10-28 |
Boston Biomedical, Inc. |
Sestave in metode za zdravljenje raka
|
CA2700665A1
(en)
|
2007-09-24 |
2009-04-02 |
Tragara Pharmaceuticals, Inc. |
Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
EP2214770A4
(en)
|
2007-11-05 |
2011-01-05 |
Puretech Ventures |
METHODS, KITS AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS
|
CN101185633A
(zh)
|
2007-12-14 |
2008-05-28 |
山东蓝金生物工程有限公司 |
一种治疗实体肿瘤的尼拉替尼缓释植入剂
|
JP2011505873A
(ja)
|
2007-12-18 |
2011-03-03 |
シェーリング コーポレイション |
抗igf1r療法に対する感受性のバイオマーカー
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
US20090203709A1
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
CA2716826C
(en)
|
2008-02-25 |
2017-05-09 |
Prometheus Laboratories Inc. |
Drug selection for breast cancer therapy using antibody-based arrays
|
WO2009111073A2
(en)
|
2008-03-06 |
2009-09-11 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
US20110104256A1
(en)
|
2008-03-25 |
2011-05-05 |
Yaolin Wang |
Methods for treating or preventing colorectal cancer
|
US8741861B2
(en)
|
2008-03-27 |
2014-06-03 |
Vascular Biosciences |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
US20110182888A1
(en)
|
2008-04-08 |
2011-07-28 |
Peter Ordentlich |
Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
|
MX339476B
(es)
|
2008-04-18 |
2016-05-27 |
Reata Pharmaceuticals Inc |
Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
|
ME02751B
(me)
|
2008-04-18 |
2018-01-20 |
Reata Pharmaceuticals Inc |
Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
|
WO2009129545A1
(en)
|
2008-04-18 |
2009-10-22 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
|
US8071632B2
(en)
|
2008-04-18 |
2011-12-06 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
TWI453023B
(zh)
|
2008-04-18 |
2014-09-21 |
Reata Pharmaceuticals Inc |
抗氧化發炎調節劑:在c-17處具有胺基及其他修飾之齊墩果酸衍生物
|
MX2010012064A
(es)
|
2008-05-05 |
2010-12-06 |
Schering Corp |
Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
WO2010008744A2
(en)
|
2008-06-17 |
2010-01-21 |
Wyeth |
Antineoplastic combinations containing hki-272 and vinorelbine
|
WO2010011782A1
(en)
|
2008-07-22 |
2010-01-28 |
Trustees Of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
MX2011001318A
(es)
|
2008-08-04 |
2011-03-04 |
Wyeth Llc |
Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
|
WO2010030835A2
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
EP2376087A4
(en)
|
2008-11-07 |
2013-06-05 |
Santaris Pharma As |
ERBB-3 (HER3) -ELECTIVE COMBINATION THERAPY
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
RU2011136641A
(ru)
|
2009-02-04 |
2013-03-10 |
Байпар Сайенсиз, Инк. |
Лечение рака легких с применением соединения нитробензамида в комбинации с ингибитором фактора роста
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
NZ595206A
(en)
|
2009-03-11 |
2014-02-28 |
Auckland Uniservices Ltd |
Prodrug forms of kinase inhibitors and their use in therapy
|
RU2011139363A
(ru)
|
2009-04-06 |
2013-05-20 |
ВАЙЕТ ЭлЭлСи |
Схема лечения рака молочной железы с использованием нератиниба
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
RU2011152105A
(ru)
|
2009-07-02 |
2013-08-10 |
УАЙТ ЭлЭлСи |
Составы таблеток 3-цианохинолина и их применение
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
WO2011008054A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
N,n-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
KR101190953B1
(ko)
|
2009-08-25 |
2012-10-12 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025267A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
KR101211227B1
(ko)
|
2009-08-25 |
2012-12-11 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
US20110055838A1
(en)
|
2009-08-28 |
2011-03-03 |
Moyes William A |
Optimized thread scheduling via hardware performance monitoring
|
CA2775155A1
(en)
|
2009-10-01 |
2011-04-07 |
Csl Limited |
Method of treatment of philadelphia chromosome positive leukemia
|
CN102724962B
(zh)
|
2009-11-09 |
2017-05-17 |
惠氏有限责任公司 |
包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
|
SI2498756T2
(sl)
|
2009-11-09 |
2023-04-28 |
Wyeth Llc |
Tabletne formulacije neratinib maleata
|
EP3670539A1
(en)
|
2009-11-13 |
2020-06-24 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing her-3 associated diseases
|
WO2011069962A1
(en)
|
2009-12-07 |
2011-06-16 |
Boehringer Ingelheim International Gmbh |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
EP3575413A1
(en)
|
2009-12-11 |
2019-12-04 |
Wyeth LLC |
Phosphatidylinositol-3-kinase pathway biomarkers
|
EP2524231B1
(en)
|
2010-01-13 |
2017-06-28 |
Wyeth LLC |
A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
|